Abstracts tagged "WOMAC"

Abstract Number: L08 • ACR Convergence 2024
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging and Parallel-group Study to Evaluate the Safety and Efficacy of XG005 in Subjects with Painful Osteoarthritis of the Knee
Limin Ren¹, Wenjie Zheng², Zhenpeng Guan³, Yang Zhang⁴, Zeyu Huang⁵, Tong Li⁶, Yuwei Peng⁷, Qiuli Wu⁸, Wei Gou⁹, Wei Zhao¹⁰, Pengyan Qiao¹¹, Xiaoli Pan¹² and Guang-Liang Jiang¹³, ¹Peking University, People’s Hospital, Rheumatology and Immunology Department, Beijing, China, ²Yantai Yuhuangding Hospital of Qingdao University, Department of Orthopedics, Yantai, China, ³Peking University, Shougang Hospital, Department of Orthopedics, Beijing, China, ⁴Division of Orthopaedic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, ⁵West China Hospital of Sichuan University, Department of Orthopedics, Chengdu, China, ⁶Xiangya Hospital of Central South University, Rheumatology and Immunology Department, Changsha, China, ⁷PingXiang People’s Hospital, Rheumatology and Immunology Department, Pingxiang, China, ⁸Tianjin Medical University General Hospital, Department of Orthopedics, Tianjin, China, ⁹Hebei Petrochina Central Hospital, Rheumatology and Immunology Department, Langfang, China, ¹⁰Central Hospital Affiliated to Shenyang Medical College, Department of Orthopedics, Shenyang, China, ¹¹Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Rheumatology and Immunology Department, Taiyuan, China, ¹²Affiliated Hospital of Zunyi Medical University, Rheumatology and Immunology Department, Zunyi, China, ¹³Xgene Pharmaceutical, Lexington, MA
Background/Purpose: Osteoarthritis (OA) affects 595 million people globally; cases are projected to increase 49-95% for various joints by 2050 as populations age (GBD 2023). OA…
Abstract Number: 0792 • ACR Convergence 2024
Radiographic and Pain Outcomes from a Phase 3 Trial (OA-07) Evaluating the Efficacy and Safety of Repeat Lorecivivint Injections over 3 Years in Subjects with Knee OA
Yusuf Yazici¹, Jeyanesh Tambiah², Christopher Swearingen³ and Timothy McAlindon⁴, ¹NYU Grossman School of Medicine, La Jolla, CA, ²Biosplice Therapeutics Inc., San Diego, CA, ³Biosplice Therapeutics, Inc, San Diego, CA, ⁴University of Massachusets, Worchester, MA
Background/Purpose: Knee OA has unmet need for safe and efficacious symptom and disease-modifying treatments. Lorecivivint (LOR), an intra-articular (IA) CLK/DYRK inhibitor thought to modulate inflammatory…
Abstract Number: 1184 • ACR Convergence 2024
Sustained Clinical Effects After a Single Intra-articular Injection of PCRX-201 for Moderate-to-Severe Osteoarthritis of the Knee
Stanley Cohen¹, Philip G Conaghan², Marc Hochberg³, Alan Kivitz⁴, Nino Joy⁵, Derek Jackson⁵, Masato Nakazawa⁵, Mary DiGiorgi⁵ and Jonathan Slonin⁵, ¹Metroplex Clinical Research Center, dallas, TX, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³University of Maryland School of Medicine, Baltimore, MD, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Pacira BioSciences, Inc., Tampa, FL
Background/Purpose: Osteoarthritis of the knee (OAK) is a common and severe disease. Current treatments provide temporary pain relief, demonstrating unmet need. PCRX-201 is a high…
Abstract Number: 1187 • ACR Convergence 2024
Association of Depressive Symptoms and Multiple Joint Osteoarthritis with Pain Outcomes in the WE-CAN Trial
Natalie Allcott¹, Stephen Messier², Shannon Mihalko², Jeffrey Katz³, Paul DeVita⁴, David Hunter⁵, Sara Quandt⁶, Carolina Alvarez⁷, Leigh Callahan⁸ and Amanda Nelson¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Wake Forest University, Winston Salem, NC, ³Brigham and Women's Hospital, Brookline, MA, ⁴Eastern Carolina University, Greenville, ⁵Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ⁶Wake Forest University, Winston-Salem, ⁷University of North Carolina at Chapel Hill, Miami, FL, ⁸University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC
Background/Purpose: The Weight-loss and Exercise for Communities with Arthritis in North Carolina (WE-CAN) trial was a community-based, pragmatic randomized clinical trial in men and women…
Abstract Number: 1196 • ACR Convergence 2024
Relation of Different Types of Antidepressants Use to Pain Severity and Measures of Pain Sensitization in Kneeosteoarthritis
Zhiqiang Wang¹, Brooke Mcginley², mike LaValley³, Laura Frey-Law⁴, Beth Lewis⁵, Michael Nevitt⁶, Margaret Clancy⁷, Changhai Ding⁸ and Tuhina Neogi⁷, and MOST investigators, ¹Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, Guangdong, China (People's Republic), ²Boston University, Boston, MA, ³Boston University School of Public Health, Arlington, MA, ⁴Carver College of Medicine, Iowa City, IA, ⁵School of Kinesiology , Kinesiology College of Education and Human Development, Twin Cities, Minneapolis, MN, ⁶UCSF, Orinda, CA, ⁷Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁸Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China (People's Republic)
Background/Purpose: The pain experience in osteoarthritis (OA) is multifactorial and includes both somatosensory and affective components. The affective component can be related to depression, a…
Abstract Number: 1199 • ACR Convergence 2024
Diclofenac Sodium 1% Gel Improves Physical Function in the Performance of Important Activities of Daily Living in Patients with Hand or Knee Osteoarthritis
Karin Nicholson, Edwin Sanchez, Nadine Maybaum and Richard Petruschke, Haleon, Warren, NJ
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis, with hand and knee being among the most afflicted joints. Symptoms of OA include joint…
Abstract Number: 1204 • ACR Convergence 2024
Immunobased Profiling of Knee Osteoarthritis Patients to Predict Response to Regenerative Treatment with Autologous Blood-derivative Platelet-Rich Plasma Injection
Antonio Tonutti¹, Valentina Granata², Veronica Marrella², Cristina Sobacchi², Rita Ragusa³, Marzia Monferini³, Cristiano sconza³, Nicola rani⁴, Berardo Di Matteo⁵, Carlo Selmi⁶ and Angela Ceribelli⁵, ¹Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, Italy, ²Humanitas Research Hospital and Institute for Genetic and Biomedical Research, Rozzano, Italy, ³Humanitas Research Hospital, Rozzano, Italy, ⁴Rizzoli Orthopaedic Institute, Bologna, Italy, ⁵Humanitas University and Humanitas Research Hospital, Rozzano, Italy, ⁶Department of Biomedical Sciences, Humanitas University, Rozzano, Italy
Background/Purpose: Osteoarthritis (OA) is a degenerative musculoskeletal disease causing chronic disability and elevated social costs worldwide. Its multifactorial origin contributes to different OA phenotypes and…
Abstract Number: L04 • ACR Convergence 2023
EP-104IAR (Extended-Release Fluticasone Propionate for Injectable Suspension): Topline and Key Secondary Results from a Phase 2 Randomized, Double-blind, Vehicle-Controlled Trial in Subjects with Knee Osteoarthritis
James Helliwell¹, Amanda Malone¹, Mark Kowalski², Asger Reinstrup Bihlet³, Claire Miller⁴, Alejandro Castillo Mondragon⁵, Yanqi Li⁶, Christine Dobek⁷, Vik Peck¹, Mike Wilmink⁸ and Lee Simon⁹, ¹Eupraxia Pharmaceuticals, Victoria, BC, Canada, ²Eupraxia Pharmaceuticals, Winchester, VA, ³NBCD A/S, Soeborg, Denmark, ⁴NBCD A/S, Copenhagen, Denmark, ⁵NBCD, Copenhagen, Denmark, ⁶NBCD A/S, Soborg, Denmark, ⁷Eupraxia Pharmaceuticals, Edmonton, AB, Canada, ⁸OrthoArizona, Phoenix, AZ, ⁹SDG LLC, Cambridge, MA
Background/Purpose: EP-104IAR is being developed to treat OA symptoms. Previous results from non-clinical studies evaluating local joint safety in beagle dogs, in contrast to other…
Abstract Number: L19 • ACR Convergence 2023
A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks
George Spencer-Green¹, David Hunter², Thomas Schnitzer³, Sheue-Fang Shih⁴, Tien-Tzu Tai⁴, Cathy Kao⁴ and Siao-Ning Huang⁴, ¹Taiwan Liposome Company, Cambridge, MA, ²Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Taiwan Liposome Company, Taipei, Taiwan (Republic of China)
Background/Purpose: In osteoarthritis (OA) of the knee, intraarticular injections of corticosteroids can relieve pain, reduce inflammation, and improve mobility, but the effect is not predictable,…
Abstract Number: 0820 • ACR Convergence 2023
Radiographic and Pain Outcomes from a Phase 3 Extension Study Evaluating the Safety and Efficacy of Lorecivivint in Subjects with Severe Osteoarthritis of the Knee (OA-07): 36 Month Single Blind and Placebo Crossover Phase Results
Yusuf Yazici¹, Christopher Swearingen², Victor Lopez³, Jon Britt⁴, Sarah Kennedy⁵, Jeyanesh Tambiah² and Timothy McAlindon⁶, ¹NYU Grossman School of Medicine, La Jolla, CA, ²Biosplice Therapeutics, Inc., San Diego, CA, ³Biosplice Therapeutics, Inc., Santa Clarita, CA, ⁴Biosplice Therapeutics, Inc., Los Angeles, CA, ⁵Biosplice Therapeutics, Inc., Superior, CO, ⁶Tufts Medical Center, Arlington, MA
Background/Purpose: Knee osteoarthritis (OA) has unmet need for safe, efficacious symptom and disease-modifying treatments. Lorecivivint (LOR), an intra-articular (IA) CLK/DYRK inhibitor thought to modulate Wnt…
Abstract Number: 1197 • ACR Convergence 2023
Efficacy and Safety of a Single Intra-Articular Injection of MM-II, a Novel Suspension of Large, Empty, Multilamellar Liposomes, in People with Painful Knee OA: Results of a 26-Week, Phase 2b, Placebo-Controlled, Double-Blind, Randomized Trial
Schnitzer Thomas¹, Helene Rovsing², Edith Lau³, Sidsel Boll⁴, Ballari Brahmachari⁵, Richard Chou⁶, Tarini Joshi⁵, Roni Wechsler⁷, Siu-Long Yao⁵, Sveta Weiner⁵, Asger Bihlet⁸ and Philip Conaghan⁹, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Sanos Clinic, Gandrup, Denmark, ³Hong Kong Center for Clinical Research, Hong Kong, China, ⁴Sanos Clinic, Vejle, Denmark, ⁵Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁶Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, NY, ⁷Moebius Medical, Tel Aviv, Israel, ⁸NBCD, Soeborg, Denmark, ⁹University of Leeds, Leeds, United Kingdom
Background/Purpose: Safe and effective therapies are needed for OA pain. MM-II, a novel suspension of large, empty, multilamellar liposomes composed of dimyristoylphosphatidylcholine and dipalmitoylphosphatidylcholine, effectively…
Abstract Number: 1992 • ACR Convergence 2023
Association Between Knee Osteoarthritis Pain and Concomitant Drug Use: A Post-hoc Analysis of Two Phase 3 Clinical Trials
Claire Miller¹, Matthew Baker², Peter Alexandersen³, Alejandro Mondragón¹, Ida Sofie Adrian¹, Morten Karsdal⁴, Jeppe Andersen⁵ and Asger Bihlet¹, ¹NBCD, Soeborg, Denmark, ²Stanford University, Menlo Park, CA, ³Sanos Clinics, Gandrup, Denmark, ⁴Nordic Bioscience, Herlev, Denmark, ⁵Sanos Group, Soeborg, Denmark
Background/Purpose: Patients with knee osteoarthritis are often overweight and suffer from comorbidities, which are frequently treated pharmacologically. Our understanding of the potential disease-modifying and/or symptom-modifying…
Abstract Number: 1307 • ACR Convergence 2022
Effect of Romosozumab in Postmenopausal Women with Knee Osteoarthritis: Results from the FRAME Clinical Trial
Nancy Lane¹, Donald Betah², Cynthia Deignan², Mary Oates², Zhenxun Wang², Jen Timoshenko³, Aliya Khan⁴ and Neil Binkley⁵, ¹University of California Davis, Hillsborough, CA, ²Amgen, Inc., Thousand Oaks, CA, ³UCB Pharma, Slough, United Kingdom, ⁴McMaster University, Oakville, ON, Canada, ⁵University of Wisconsin, Madison, WI
Background/Purpose: Osteoarthritis (OA) and osteoporosis (OP) often occur concomitantly in the elderly. The relationship between OA and OP is complex, with increased fracture risk reported…
Abstract Number: 1813 • ACR Convergence 2022
Patient-Reported Outcomes in CPPD Compared to Gout and Osteoarthritis
Mary Grace Whelan¹, Keigo Hayashi² and Sara Tedeschi¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Okayama, Japan
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease prevalence is similar to gout and osteoarthritis (OA), yet CPPD outcomes research greatly lags behind these other forms of…
Abstract Number: 1895 • ACR Convergence 2022
Association Between Synovial Tissue Metabolomic Profile and Pain in Patients with Knee Osteoarthritis
Jessica Murillo Saich¹, Roxana Coras², Robert Meyer³, Nancy Lane⁴ and Monica Guma⁵, ¹University of California San Diego, La Jolla, CA, ²University of California San Diego, San Diego, CA, ³San Diego VA Healthcare Service, San Diego, CA, ⁴University of California Davis, Hillsborough, CA, ⁵UCSD, La Jolla, CA
Background/Purpose: Increasing evidence indicates that osteoarthritis (OA) progression is mediated by low-grade synovial inflammation (synovitis) that contributes to joint pain and stiffness, especially in knee…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].